QuiaPEG Pharmaceuticals Holding AB - Asset Resilience Ratio
QuiaPEG Pharmaceuticals Holding AB (QUIA) has an Asset Resilience Ratio of 14.02% as of March 2017. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read QUIA total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2010)
This chart shows how QuiaPEG Pharmaceuticals Holding AB's Asset Resilience Ratio has changed over time. See what is QuiaPEG Pharmaceuticals Holding AB's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down QuiaPEG Pharmaceuticals Holding AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of QuiaPEG Pharmaceuticals Holding AB.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr3.36 Million | 14.02% |
| Total Liquid Assets | Skr3.36 Million | 14.02% |
Asset Resilience Insights
- Moderate Liquidity: QuiaPEG Pharmaceuticals Holding AB has 14.02% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
QuiaPEG Pharmaceuticals Holding AB Industry Peers by Asset Resilience Ratio
Compare QuiaPEG Pharmaceuticals Holding AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for QuiaPEG Pharmaceuticals Holding AB (2010–2010)
The table below shows the annual Asset Resilience Ratio data for QuiaPEG Pharmaceuticals Holding AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2010-12-31 | 24.43% | Skr4.86 Million ≈ $522.48K |
Skr19.88 Million ≈ $2.14 Million |
-- |
About QuiaPEG Pharmaceuticals Holding AB
Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as… Read more